First US Patient Enrolled in SELUTION SLR IDE Peripheral Study - 24 August 2022 11:00

GENEVA, Switzerland, Aug. 24, 2022 /PRNewswire-AsiaNet/ - The first US patient has been enrolled in the FDA SELUTION4BTK (Below-the-Knee) clinical trial evaluating SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon. This milestone follows Investigational Device Exemption (IDE) approval in t...

  Zerion Pharma and Hovione extend partnership to cover use of t... - 23 August 2022 20:16

LISBON, Portugal, Aug. 23, 2022 /PRNewswire-AsiaNet/ -- Hovione and Zerion Pharma A/S (Zerion) today announced an extension of their collaboration on Zerion's Dispersome(R) technology into the nutraceutical/dietary supplements field. Many dietary supplements suffer from low solubility. This results in ...

  Prominent ophthalmologist will guide Turn Bio's search for the... - 22 August 2022 22:00

MOUNTAIN VIEW, Calif., Aug. 22, 2022 /PRNewswire-AsiaNet/ -- -- Albert Wu, MD, PhD, a recognized advocate of using stem cell therapy to treat eye conditions, will advise company's development of ocular tissue rejuvenation therapeutics Turn Biotechnologies, a cell rejuvenation company developing novel mRN...

  Menarini Group's Elacestrant Marketing Authorization Applicati... - 19 August 2022 19:30

FLORENCE, Italy and NEW YORK, Aug. 19, 2022 / PRNewswire-AsiaNet/ -- - Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union ...

  Kronos Bio and Invivoscribe Partner on Companion Diagnostic fo... - 17 August 2022 06:05

SAN MATEO, Calif. and SAN DIEGO, Aug. 17, 2022 /PRNewswire-AsiaNet/ -- - Companion diagnostic would be used following potential regulatory approval of entospletinib to screen for NPM1 mutation present in approximately one-third of all patients with AML - Entospletinib is currently being studied in the Phase 3 AGIL...

  Menarini Group's Elacestrant Granted Priority Review by the U.... - 11 August 2022 22:12

FLORENCE, Italy and NEW YORK, August 11, 2022 /PRNewswire-AsiaNet/ -- Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast cancer Submission supported by results from the pivotal ...

  MedAlliance SELUTION SLR Receives Second FDA IDE Approval - 10 August 2022 11:00

GENEVA, Aug. 10, 2022 /PRNewswire-AsiaNet/ -- SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of occlusive disease of the superficial femor...

  Novaliq Submits New Drug Application Seeking Approval For Firs... - 09 August 2022 21:00

HEIDELBERG, Germany, and CAMBRIDGE, MA, August 9, 2022, /PRNewswire-AsiaNet/-- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol(R) water-free technology, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administrat...

  FRONTIER BIOTECHNOLOGIES ANNOUNCES POSITIVE PHASE 1 RESULTS OF... - 09 August 2022 02:44

ATLANTA, Aug. 9, 2022 /PRNewswire-AsiaNet/ -- - FB2001 (Bofutrelvir) is a Coronavirus Mpro inhibitor, which exhibited potent anti-SARS-CoV-2 activity in vitro and in vivo - Phase 1 results show FB2001 to be generally safe and well tolerated. No significant difference was observed between Chi...

  HISTORY OF HYPERTENSIVE DISORDERS DURING PREGNANCY LINKED TO I... - 03 August 2022 22:00

SAN DIEGO, Aug. 3, 2022 /PRNewswire-AsiaNet/ -- Experiences of high blood pressure disorders during pregnancy are associated with an increased risk of vascular dementia and accelerated brain aging, according to studies reported today at the Alzheimer's Association International Conference(R)) (...